ReviewPharmaceutical research2019
Sizing up the Next Generation of Nanomedicines.
Review in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.International journal of nanomedicine · 2026Review
- AF4-to-SAXS: expanded characterization of nanoparticles and proteins at the P12 BioSAXS beamline.Journal of synchrotron radiation · 2025Article
- Current state of nanomedicine drug products: An industry perspective.Journal of pharmaceutical sciences · 2024Article
- Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System.Pharmaceutics · 2024Review
- Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment.Pharmaceutics · 2024Article
- Cannabidiol-Loaded Solid Lipid Nanoparticles Ameliorate the Inhibition of Proinflammatory Cytokines and Free Radicals in an In Vitro Inflammation-Induced Cell Model.International journal of molecular sciences · 2024Article
- Regulatory aspects of a nanomaterial for imaging therapeutic cells.Drug delivery and translational research · 2023Article
- Quantitative size-resolved characterization of mRNA nanoparticles by in-line coupling of asymmetrical-flow field-flow fractionation with small angle X-ray scattering.Scientific reports · 2023Article
- Current status of nano-vaccinology in veterinary medicine science.Veterinary medicine and science · 2023Review
- In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate.International journal of pharmaceutics · 2023Article
- Characterization Challenges of Self-Assembled Polymer-SPIONs Nanoparticles: Benefits of Orthogonal Methods.International journal of molecular sciences · 2022Article
- The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.Pharmaceutics · 2022Review
- Nanomaterials in diagnostics, imaging and delivery: Applications from COVID-19 to cancer.MRS communications · 2022Review
- A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.Annals of the New York Academy of Sciences · 2021Article
- Preparing (Metalla)carboranes for Nanomedicine.ChemMedChem · 2021Review
- A Step-by-Step Approach to Improve Clinical Translation of Liposome-Based Nanomaterials, a Focus on Innate Immune and Inflammatory Responses.International journal of molecular sciences · 2021Article
- Measuring particle concentration of multimodal synthetic reference materials and extracellular vesicles with orthogonal techniques: Who is up to the challenge?Journal of extracellular vesicles · 2021Article
- Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines.International journal of nanomedicine · 2021Review
- Emerging trends in nano- and microencapsulation science: hallmarks of the 22Drug delivery and translational research · 2020Article
- Drug delivery-the increasing momentum.Drug delivery and translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
During the past two decades the nanomedicine field has experienced significant progress. To date, over sixty nanoparticle (NP) formulations have been approved in the US and EU while many others are in clinical or preclinical development, indicating a concerted effort to translate promising bench research to commercially viable pharmaceutical products. The use of NPs as novel drug delivery systems, for example, can improve drug safety and efficacy profiles and enable access to intracellular domains of diseased cells, thus paving the way to previously intractable biological targets. However, the measurement of their physicochemical properties presents substantial challenges relative to conventional injectable formulations. In this perspective, we focus exclusively on particle size, a core property and critical quality attribute of nanomedicines. We present an overview of relevant state-of-the-art technologies for particle sizing, highlighting the main parameters that can influence the selection of techniques suitable for a specific size range or material. We consider the increasing need, and associated challenge, to measure size in physiologically relevant media. We detail the importance of standards, key to validate any measurement, and the need for suitable reference materials for processes used to characterize novel and complex NPs. This perspective highlights issues critical to achieve compliance with regulatory guidelines and to support research and manufacturing quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.